O
Olivier Tredan
Researcher at University of Lyon
Publications - 247
Citations - 9430
Olivier Tredan is an academic researcher from University of Lyon. The author has contributed to research in topics: Breast cancer & Medicine. The author has an hindex of 36, co-authored 198 publications receiving 7092 citations. Previous affiliations of Olivier Tredan include University of Toronto & Centre national de la recherche scientifique.
Papers
More filters
Journal ArticleDOI
Drug Resistance and the Solid Tumor Microenvironment
TL;DR: How the tumor microenvironment may be involved in the resistance of solid tumors to chemotherapy and potential strategies to improve the effectiveness of drug treatment by modifying factors relating to the tumormicroenvironment are described.
Journal ArticleDOI
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert L. Coleman,Amit M. Oza,Domenica Lorusso,Carol Aghajanian,Ana Oaknin,Andrew Dean,Nicoletta Colombo,Johanne I Weberpals,Andrew R Clamp,Giovanni Scambia,Alexandra Leary,Robert W Holloway,Margarita Amenedo Gancedo,Peter C.C. Fong,Jeffrey C. Goh,David M. O'Malley,Deborah K. Armstrong,Jesus Garcia-Donas,Elizabeth M. Swisher,Anne Floquet,Gottfried E. Konecny,Iain A. McNeish,Clare L. Scott,Terri Cameron,Lara Maloney,Jeff Isaacson,Sandra Goble,Caroline Grace,Thomas Harding,Mitch Raponi,James Sun,Kevin K. Lin,Heidi Giordano,Jonathan A. Ledermann,Martin Buck,A Dean,Michael Friedlander,J C Goh,Paul R. Harnett,G Kichenadasse,C L Scott,H Denys,Luc Dirix,Ignace Vergote,Laurie Elit,Prafull Ghatage,Amit M. Oza,Marie Plante,Diane Provencher,J I Weberpals,Stephen Welch,A Floquet,Laurence Gladieff,Florence Joly,A Leary,Alain Lortholary,Jean-Pierre Lotz,J. Medioni,Olivier Tredan,Benoit You,A El-Balat,C Hänle,P Krabisch,T Neunhöffer,M Pölcher,Pauline Wimberger,Amnon Amit,S Kovel,M Leviov,Tamar Safra,Ronnie Shapira-Frommer,Salomon M. Stemmer,Alessandra Bologna,N Colombo,Domenica Lorusso,Sandro Pignata,Roberto Sabbatini,G Scambia,Stefano Tamberi,Claudio Zamagni,P C Fong,A O'Donnell,M Amenedo Gancedo,A Casado Herraez,J Garcia-Donas,E M Guerra,A Oaknin,I Palacio,Iris L. Romero,A Sanchez,Susana Banerjee,A Clamp,Y Drew,Hani Gabra,D Jackson,Jonathan A. Ledermann,I A McNeish,Christine Parkinson,Melanie E Powell,C Aghajanian,D K Armstrong,Michael J. Birrer,Mary K. Buss,Setsuko K. Chambers,L-m Chen,Robert L. Coleman,R W Holloway,G E Konecny,L Ma,Mark A. Morgan,R T Morris,David G. Mutch,D M O'Malley,B M Slomovitz,E M Swisher,T Vanderkwaak,M Vulfovich +116 more
TL;DR: This trial assessed rucaparib versus placebo after response to second-line or later platinum-based chemotherapy in patients with high-grade, recurrent, platinum-sensitive ovarian carcinoma harbouring a BRCA mutation or high percentage of genome-wide loss of heterozygosity.
Journal ArticleDOI
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Matthew P. Goetz,Masakazu Toi,Mario Campone,Joohyuk Sohn,Shani Paluch-Shimon,Jens Huober,In Hae Park,Olivier Tredan,Shin-Cheh Chen,Luis Manso,Orit Freedman,Georgina Garnica Jaliffe,T. Forrester,Martin Frenzel,Susana Barriga,Ian C. Smith,Nawel Bourayou,Angelo Di Leo +17 more
TL;DR: Abemaciclib plus a nonsteroidal aromatase inhibitor was effective as initial therapy, significantly improving progression-free survival and objective response rate and demonstrating a tolerable safety profile in women with HR-positive, HER2-negative advanced breast cancer.
Journal ArticleDOI
Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and Lymphomas
Isabelle Ray-Coquard,Claire Cropet,Martine Van Glabbeke,Catherine Sebban,Axel Le Cesne,Ian Judson,Olivier Tredan,Jaap Verweij,Pierre Biron,Inthidar Labidi,Jean-Paul Guastalla,Thomas Bachelot,David Pérol,Sylvie Chabaud,Pancras C.W. Hogendoorn,Philippe A. Cassier,Armelle Dufresne,Jean-Yves Blay +17 more
TL;DR: Findings show that lymphopenia is an independent prognostic factor for overall and progression-free survival in several cancers.
Journal ArticleDOI
Class III β-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel
Pascal Sève,John R. Mackey,Sylvie Isaac,Olivier Tredan,Pierre-Jean Souquet,Maurice Pérol,Raymond Lai,Alain Voloch,Charles Dumontet +8 more
TL;DR: The expression levels of class III β-tubulin in tumor cells is predictive of response to therapy and patient outcome in patients with NSCLC receiving paclitaxel-based chemotherapy but is not a general prognostic factor in this patient population.